Browse studies

Find your next paid study

11 recruiting studies matching your filters

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other c…

Bladder CancerRecurrent Bladder CancerNon-muscle Invasive Bladder Cancer (NMIBC)

Estimated

~$10 – $750

Actual pay is set by the research site.

University of WashingtonNCT07225127

Phase 1

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle in…

Bladder (Urothelial, Transitional Cell) CancerNMIBCUrothelial Carcinoma Bladder+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

The SCORE-NMIBC study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with non-muscle Invasiv…

Non-Muscle Invasive Bladder CancerNMIBCHigh-risk Non-Muscle Invasive Bladder Cancer

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Natera, Inc.NCT07763197

Phase 2

Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)

The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasiv…

Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Michael A. O'DonnellNCT07322263

Observational

A Pilot Study Using Hyperthermic Irrigation Followed by Intravesical Chemotherapy in Patients With Low- to Intermediate-Risk Non-Muscle Invasive Bladder Cancer

The goal of this prospective pilot study is to evaluate the safety and feasibility of using heated saline during bladder tumor surgery in patients with non-mus…

Bladder CancerBladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)Non-muscle Invasive Bladder Cancer (NMIBC)+6 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Collection of Urine Samples to Support the Bladder EpiCheck Product Development Studies

This is a prospective, observational study to support the development of the Bladder EpiCheck kit by collecting urine samples from subjects suspected to have a…

Suspicion of Bladder CancerNMIBC Surveillance

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Nucleix Ltd.NCT07514143

Observational

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy: A Randomized Controlled Trial

Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many compl…

Bladder CancerMuscle Invasive Bladder Cancer (MIBC)Muscle Invasive Bladder Cancer Urothelial Carcinoma+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Johns Hopkins UniversityNCT07225205

Phase 2

A Phase II Clinical Study of Intravesical Ruvidar® in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") or Patients Who Are Intolerant to BCG Therapy ("Study II")

This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with Non-Muscle Invasive Bladder Cancer ("NM…

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Theralase® Technologies Inc.NCT03945162

Phase 1

ResQ133A-NMIBC: Phase 1/2 Clinical Trial of Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle inv…

NMIBC

Estimated

~$150 – $4,200

Actual pay is set by the research site.

ImmunityBio, Inc.NCT06800963

Phase 2

A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Tyra Biosciences, IncNCT06995677

Observational

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less…

Non-muscle Invasive Bladder Cancer (NMIBC)

Estimated

~$10 – $750

Actual pay is set by the research site.

Lahey ClinicNCT07187063